Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Mancilla, A."'
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
Autor:
Baltazar Gomez-Mancilla, Jean-Christophe Corvol, Gurutz Linazasoro, Izabela Rozenberg, Karla Eggert, Alberto J. Espay, Daniela Berg, Christian Geny, Pascal Derkinderen, Judit Sovago, Johannes Schwarz, Fabrizio Stocchi, Franck Durif, Andrew Feigin, Dominik Feuerbach, Jean-Luc Houeto, Thérèse Di Paolo, Claudia Trenkwalder, Judith Jaeger, Andres O. Ceballos-Baumann, Lin Zhang, Paul Maruff, Markus Weiss, Christine Tranchant, Donald Johns, Alexander Storch, Emmanuel Broussolle, Annamaria Jakab, Hans Ulrich Hockey, Olivier Rascol, Jean-Philippe Azulay, Luc Defebvre, Michal Gostkowski
Publikováno v:
Movement Disorders. 31:1049-1054
Background This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia. Methods Pati
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease
Autor:
Donald Johns, Josef Priller, Hugh Rickards, Anne Elizabeth Rosser, Ralf Reilmann, Nicole Pezous, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Sigurd D. Süssmuth, Marie-Laure Rouzade-Dominguez, Ludger Schöls, Carsten Saft, Georg Bernhard Landwehrmeyer
Publikováno v:
Movement disorders 30(3), 427-431 (2015). doi:10.1002/mds.26174
Background This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5 antagonist, reduces chorea in Huntington's disease (HD). Methods This 32-day randomized, double-blind, parallel-group, proof-of
Autor:
Igor D. Grachev, Juliana Bronzova, Johannes Streffer, Baltazar Gomez-Mancilla, Cheryl Fitzer-Attas, Stephen J. Victor, Susanne Ostrowitzki, Robert Alexander, Babak Boroojerdi, Paulo Fontoura
Publikováno v:
Movement Disorders. 27:651-655
Realizing that 60% to 80% of dopa- minergic nigrostriatal neurons are nonfunctional at the time of clinical diagnosis, there is an emerging consen- sus that disease-modifying treatments should be initi- ated in the earliest stages of Parkinson's dise
Autor:
Baltazar Gomez-Mancilla, Adriana Di Santo, Adriane Gröger, Ann-Kathrin Hauser, Thomas Gasser, Walter Maetzler, Claudia Schulte, Daniela Berg, Uwe Klose, Ruediger Hilker, Inga Liepelt, Kathrin Brockmann
Publikováno v:
Movement disorders 26(13), 2335-2342 (2011). doi:10.1002/mds.23991
The objective of this research was to evaluate a possible endophenotype in leucine-rich repeat kinase 2 (LRRK2)-associated Parkinson's disease (PD). Ten symptomatic LRRK2 patients, 24 sporadic Parkinson's disease patients as well as 10 asymptomatic L
Autor:
Sam Hariry, Vincent Ries, Jana Godau, Fabrizio Gasparini, Monica Morelli-Canelo, Christine Schneider, Donald Johns, Walid M. Abi-Saab, Marc Vandemeulebroecke, Karla Eggert, Baltazar Gomez-Mancilla, Daniela Berg, Katy Cooke, Maria Stamelou, IIona Csoti, Heiko Huber, Martin Wolz, Thérèse Di Paolo, Claudia Trenkwalder, Alexander Storch
Publikováno v:
Movement Disorders. 26:1243-1250
Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa-induced dyskinesia. Two randomized, double-blind, placebo-controlled, parallel-group, in-patient studies for Parkinson's di
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Paul J. Bédard, René Boucher, Céline Gagnon, Rudolf Markstein, Thérèse Di Paolo, Baltazar Gomez-Mancilla
Publikováno v:
Movement Disorders. 8:144-150
A group of four cynomolgus monkeys previously rendered parkinsonian by the toxin 1-methyl-4-phenyl, 1, 2, 3, 6-tetrahydropyridine (MPTP) were observed in locomotion cages equipped with photocells during four periods of 7 days during which they receiv
Publikováno v:
Movement Disorders. 7:137-141
Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a
Publikováno v:
Movement Disorders. 7:43-47
The antitremor effect of the D2 agonist LY 171555 and of the D1 agonist CY 208-243 alone and in combination was tested in a monkey previously rendered parkinsonian by MPTP and displaying exceptionally a rest termor in the limbs. The D2 agonist suppre